Acalabrutinib plus obinutuzumab shows superior long-term outcomes in treatment-naive chronic lymphocytic leukemia.

Several pharmaceutical companies showcased data on their BTK inhibitors at the ASCO 2023 conference, including Ono ...

Recent developments in the treatment of chronic lymphocytic leukemia (CLL) have included a fixed-duration oral combination regimen for untreated patients and promising results with a Bruton's tyrosine ...

NRIX stock is rated Strong Buy as bexobrutideg advances in CLL trials. See here for NRIX stock's milestones, market potential ...

MIAMI, FLORIDA (EMBARGOED UNTIL FEB. 1, 2024, AT 2 P.M. ET) – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating ...

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center ...

Chronic lymphocytic leukemia (CLL) is a type of blood cancer that causes your bone marrow to make too many of a type of white blood cells called lymphocytes. Unlike other types of leukemia, it’s a ...

Chronic lymphocytic leukemia (CLL), is a type of cancer that affects a type of white blood cell in your body called a lymphocyte. White blood cells are made in your bone marrow and help your body ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Open-Source Hybrid Large Language Model Integrated System for Extraction of Breast Cancer Treatment Pathway From Free-Text Clinical Notes The diagnosis of chronic lymphocytic leukemia (CLL) is often ...